<p><strong>Pediatric Use</strong>: Safety and effectiveness of Ertapenem in pediatric patients 3 months to 17 years of age are supported by evidence from adequate and well-controlled trials in adults, pharmacokinetic data in pediatric patients, and additional data from comparator-controlled trials in pediatric patients 3 months to 17 years of age.<br />
<br />
<strong>Geriatric Use</strong>: This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function<br />
<br />
<strong>Patients with Renal Impairment</strong>: Dosage adjustment is necessary in patients with creatinine clearance 30 mL/min or less.<br />
<br />
<strong>Patients with Hepatic Impairment</strong>: The pharmacokinetics of ertapenem in patients with hepatic impairment have not been established.</p>